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Objectives: Prior research has estimated the burden of opioid abuse in the 
U.S. However, older data may not reflect recent trends in abuse prevalence and 
associated costs. This study provides updated estimates of the burden of opioid 
abuse. MethOds: Patients aged 12-64 diagnosed with opioid abuse/dependence 
(“abusers”) were selected from the Truven MarketScan medical and pharmacy 
claims database, 2009-2012. A 12-month follow-up period centered on the index 
date (i.e., first abuse diagnosis) was used to assess costs and was preceded by a 
6-month baseline period. Patients were required to have continuous non-HMO cov-
erage throughout the 18-month study period. Potential controls met similar inclu-
sion criteria but were not diagnosed with abuse, with their index date based on a 
random medical claim. Abusers were matched 1:1 to controls based on index year, 
baseline health care costs, and propensity score to account for baseline differences. 
Per-patient health care costs of abusers and matched controls were compared to 
determine the excess annual health care costs of diagnosed abuse. Costs reflect 
payments from payers to providers in 2012USD. Prevalence of abuse was estimated 
as the proportion of abusers among those with ≥ 1 one month of eligibility in a given 
year. Results: 38,876 abusers and 955,202 controls met the inclusion criteria. 35,828 
(92.2%) abusers were successfully matched. Post-matching, baseline characteristics 
were well-balanced. Abusers had $11,319 higher annual total health care costs than 
matched controls ($22,132 vs. $10,813) in the follow-up period. Costs were higher 
for abusers in all cost categories: inpatient, emergency department, outpatient, and 
prescription drug costs [all p-values < 0.001]. Diagnosed abuse prevalence increased 
from 0.16% in 2009 to 0.27% in 2012. cOnclusiOns: We find substantial excess 
health care costs of opioid abuse, consistent with prior research. The rising preva-
lence of abuse suggests a growing economic burden but may also reflect increased 
physician awareness of previously undiagnosed patients.
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Objectives: Binge eating disorder (BED), the most common eating disorder, lacks 
a specific ICD-9 diagnosis code. With BED subsumed under “eating disorder not 
otherwise specified (EDNOS),” which includes other disorders, patient identification 
using medical claims data is problematic. This study used natural language pro-
cessing (NLP) to identify patients with BED and compared their health care costs to 
patients with EDNOS without BED (EDNOS-only) and to matched-patients without 
an eating disorder (Non-ED). MethOds: An NLP algorithm identified adults with 
BED from clinical notes in the Veterans Health Administration electronic health 
record database from 2005-2011 . EDNOS-only patients were identified using ICD-9 
code (307.50) and those with NLP-identified BED were excluded. The first diagno-
sis date defined the index date for both groups. Non-ED patients were randomly 
matched up to 4:1 to patients with BED, matched on age, sex, BMI, depression diag-
nosis, and index month. Total health care, inpatient, outpatient, and pharmacy 
costs were examined and reported in 2011 US$. Generalized linear models were 
used to compare total one-year health care costs while adjusting for patient char-
acteristics, including baseline costs. Results: There were 257 BED, 760 EDNOS-
only, and 823 matched Non-ED patients identified. The mean (SD) total unadjusted 
one-year costs were $33,716 ($38,928) for BED, $37,052 ($40,719) for EDNOS-only, 
and $19,548 ($35,780) for Non-ED patients. The largest component of costs for each 
was pharmacy (BED $21,842, EDNOS-only $26,426, and Non-ED $12,062) followed 
by inpatient (BED $8,483, EDNOS-only $5,892, and Non-ED $4,079) and outpatient 
costs (BED $3,391, EDNOS-only $4,735, and Non-ED $3,407). When adjusting for 
patient characteristics, BED patients had one-year total health care costs $5,589 
higher than EDNOS-only (p= 0.06) and $18,152 higher than matched Non-ED patients 
(p< 0.001). cOnclusiOns: Patients with BED had comparable costs to EDNOS 
patients and significantly higher adjusted costs than Non-ED patients. BED patients 
comprise a population with high clinical burden and health care utilization.
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Objectives: Opioid abuse is associated with annual per-patient excess health care 
costs exceeding $20,000. Some patients have considerably higher costs, however, 
and little is known about their characteristics. This study examined the charac-
teristics of high-cost patients diagnosed with opioid abuse. MethOds: Patients 
aged 12-64 diagnosed with opioid abuse/dependence (“abuse”) were identified in 
OptumHealth Reporting and Insights medical and pharmacy claims data, 2006-2012. 
Patients were required to have continuous non-HMO coverage over a 12-month 
follow-up period centered on an index date (i.e., date of first abuse diagnosis) and 
a 6-month baseline period preceding the follow-up period. Patients in the top 20% 
of total health care costs in the follow-up period were classified as “high-cost,” with 
the remainder considered “low-cost.” Patient characteristics and health care costs 
were compared between high-cost and low-cost patients using chi-squared tests 
and Wilcoxon rank-sum tests. Results: 9,291 patients diagnosed with abuse were 
identified (1,859 high-cost patients; 7,432 low-cost patients). High-cost patients were 
older (42.5 vs. 36.1; p< 0.001) and more likely to be female (55.9% vs. 42.9%%; p< 0.001). 
They had a higher comorbidity burden at baseline, as reflected in the Charlson 
Comorbidity Index (0.8 vs. 0.2; p< 0.001). High-cost patients also had higher rates 
of non-opioid substance abuse diagnoses (12.4% vs. 8.9%; p< 0.001) and psychotic 
response to response during the titration period was estimated using the predicted 
treatment response rates estimated by a previously published matching-adjusted 
indirect comparison (MAIC); mean change in ADHD-RS-IV total score from base-
line to endpoint was the efficacy outcome. The incidence rates of adverse events 
were based on those observed in the clinical trials included in the MAIC. Analyses 
were conducted from both a societal and a Canadian Ministry of Health (MoH) 
perspective over a 1-year time horizon with weekly cycles. Deterministic and 
probabilistic sensitivity analyses (PSA) were conducted to assess the robustness 
of the base-case results. Results: Compared with ATX, GXR was a dominant 
strategy (lower cost and improved efficacy) from a societal perspective, while it 
was associated with an incremental cost-effectiveness ratio (ICER) of $57,866/
QALY from a Canadian MoH perspective. Results of the PSA indicated that the 
ICER remains below the $50,000 willingness to pay threshold in 93.4% and 61.3% 
of the simulations from a societal and a Canadian MoH perspective, respec-
tively. cOnclusiOns: This analysis found that GXR was cost-effective relative 
to ATX in a majority of scenarios and perspectives in the treatment of children 
and adolescents with ADHD in Canada.
PMH32
cosT-effecTiveness of guanfacine exTended-release as an 
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Objectives: Attention-deficit/hyperactivity disorder (ADHD) is a common 
childhood disorder with a global prevalence of 2.2 to 17.8%. In the case of an 
inadequate response to stimulant medication, a combination therapy of stimu-
lants and adjunctive medication may improve the control of ADHD symptoms, 
reduce dose-limiting adverse events, and help manage comorbidities. The objec-
tive was to assess the economic impact of guanfacine extended-release (GXR) 
in combination with long-acting stimulants compared to long-acting stimulant 
monotherapy in the treatment of children and adolescents with ADHD from a 
Canadian perspective. MethOds: A Markov model was developed to assess the 
cost-effectiveness of GXR in combination with a long-acting stimulant compared 
to long-acting stimulant monotherapy. Health states were defined based on the 
clinician-reported Clinical Global Impressions-Severity (normal, mild, moder-
ate, and severe). Transition probabilities were calculated based on patient-level 
data from a published study. Long-acting stimulants available in Canada were 
considered in the base-case model: amphetamine mixed salts, methylphenidate 
HCl formulations, and lisdexamfetamine dimesylate. Analyses were conducted 
from both a Canadian Ministry of Health (MoH) and a societal perspective over 
a 1-year time horizon with weekly cycles. Deterministic and probabilistic sensi-
tivity analyses (PSA) were conducted to assess the robustness of the base-case 
results. Results: Compared to long-acting stimulant monotherapy, GXR with a 
long-acting stimulant was associated with incremental cost-effectiveness ratios 
of $23,720/QALY and $11,845/QALY from a Canadian MoH and a societal perspec-
tive, respectively. PSA of GXR as an adjunctive therapy to long-acting stimulants 
showed that it remains a cost-effective strategy in 100% of the simulations from 
both perspectives in numerous sensitivity analyses, according to a willingness to 
pay of $50,000/QALY. cOnclusiOns: This economic evaluation demonstrates that 
GXR as an adjunctive therapy to a long-acting stimulant is a cost-effective strategy 
compared to long-acting stimulant monotherapy in the treatment of children and 
adolescents with ADHD in Canada.
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Objectives: This real-world retrospective study aims at comparing re-hospitali-
zation patterns and costs among patients with schizophrenia receiving paliperi-
done palmitate (PP) or oral antipsychotics (AP) in an inpatient setting. MethOds: 
Hospital discharge and billing records from the Premier Perspective Comparative 
Hospital Database were analyzed for adult patients who had a schizophrenia-related 
hospitalization with either PP or oral AP treatment (index hospitalization) between 
1/2009 and 3/2012 and no evidence of prior treatment with other long-acting AP. 
Inverse probability of treatment weights (IPTW) based on propensity scores were 
used to weight cohorts in order to reduce confounding. Patients treated with PP 
during their index hospitalization were compared to those treated with oral AP in 
terms of re-hospitalizations and ER visits using the Andersen-Gill Cox extension 
of multivariate Cox proportional hazard models. Hospital costs (re-hospitaliza-
tions, ER, and hospital outpatient visits) of patients treated with PP were com-
pared to those of patients treated with oral AP using a multivariate generalized 
linear model regression that was weighted by the combined weight of the IPTW 
and the observation period length. Results: After applying IPTW, weighted mean 
age was 43.4 years for PP (N= 374; N weighted= 19,526) and 45.6 years for oral AP 
(N= 45,251; N weighted= 26,099) patients. The risk of all-cause re-hospitalizations 
or ER visits was significantly lower for the PP cohort compared to the oral AP cohort 
(hazard ratio [HR], [95%CI] = 0.61, [0.59;0.63] p< .0001). Similarly, hospital costs six 
months after index hospitalization were lower for the PP cohort compared to the 
oral AP cohort (adjusted mean monthly cost difference [95%CI]: - $404[-781;-148], 
p< .0001). cOnclusiOns: This hospital database analysis using the IPTW method 
found that, compared with oral AP, PP was associated with a lower risk of an ER visit 
and re-hospitalization in patients with schizophrenia receiving antipsychotics in 
the hospital setting, resulting in lower hospital costs.
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were matched from each cohort. The bipolar cohort had higher percentages of inpa-
tient stays (18.72% vs. 2.56%, p< 0.0001) and emergency room (ER) (22.51% vs. 7.82%, 
p< 0.0001), physician office (99.40% vs. 55.89%, p< 0.0001), outpatient (99.55% vs. 
56.73%, p< 0.0001) and pharmacy visits (91.83% vs. 54.65%, p< 0.0001). Bipolar disorder 
patients also incurred higher inpatient ($6,126 vs. $775, p< 0.0001), ER visit ($265 vs. 
$72, p< 0.0001), physician office visit ($4,149 vs. $1,365, p< 0.0001), outpatient visit 
($4,566 vs. $1,538), pharmacy ($952 vs. $414, p< 0.0001) and total costs ($11,645 vs. 
$2,728, p< 0.0001) compared to patients without the disorder. cOnclusiOns: In this 
study, bipolar disorder was associated with higher health care resource utilization 
and a significantly higher economic burden.
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Objectives: The purpose of this study was to describe the resource use before, and 
after, initiation of long-acting injectable antipsychotics (LAI-AP) using the provincial 
public drug reimbursement program database of the Régie de l’assurance maladie du 
Québec (RAMQ). MethOds: Patients who were incident users (no use in the previous 
12 months) of a LAI-AP prescribed between January 1st 2008 and March 31st 2012, 
at least 20 years old, with a diagnosis of schizophrenia/schizoaffective disorder 
and with continuous enrollment during the study period were selected. Resource 
utilization and associated costs were analyzed both during the year before LAI-AP 
initiation (pre-initiation period) and the year after (post-initiation period). Results: 
A total of 1,992 patients met the inclusion criteria. The average age was 43.5 years 
(SD= 14.3). In pre-initiation period, 1,484 patients had at least one hospitalization, 
compared to 958 in post-initiation period (p< 0.001), and the number of days hospi-
talized was reduced by half (40.5 days [SD= 39.6] vs. 21.2 days [SD= 29.9]; p< 0.001). 
The number of patients having at least one emergency room visit decreased from 
1,372 to 813 patients (p< 0.001), but the number of patients with at least one outpa-
tient clinic visit increased from 1,572 to 1,726 patients (p< 0.001). The pre-initiation 
inpatient costs were CDN$21,312 (SD= 27,303), compared to CDN$7,199 (SD= 16,419) 
in post-initiation period (p< 0.001). The outpatient costs were CDN$1,209 (SD= 1,173) 
during the pre-initiation period, and CDN$1,296 (SD= 1,284) in the post-initiation 
period (p= 0.002), while cost of medication were CDN$1,861 (SD= 2,515) vs. CDN$4,595 
(SD= 3,910) (p< 0.001). Total cost of health care resource, including LAI-AP, were 
CDN$24,382 (SD= 27,234) in the pre-initiation period, compared to CDN$13,090 
(SD= 16,987) in the post-initiation period (p< 0.001). cOnclusiOns: The initiation 
of LAI-AP resulted in significantly lower health care resource and cost reduction, 
with the primary driver being a reduction in number of hospitalizations, days of 
hospitalization and visits to the emergency room.
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Objectives: Even with increasing attention given to post-traumatic stress disor-
der (PTSD), limited data exist documenting PTSD-related economic burden. This 
study documents annual rates of PTSD-related hospitalizations in the US (2000-
2010), along with associated costs and length of stay [LOS]. MethOds: Adult (18+ 
years old) PTSD-related hospitalizations (those with an ICD-9-CM diagnosis code 
of 309.81 [primary or secondary]) from the 2000 through 2010 HCUP Nationwide 
Inpatient Samples (NIS) were analyzed. Annual rates of PTSD hospitalization per 
100,000 adults (adjusted to 2010 US population) were estimated using NIS sampling 
weights and US Census population denominators. Additionally, cost (in 2013 $) and 
LOS estimates were calculated. Results: Rates of hospitalizations with a primary 
diagnosis of PTSD have increased over time, from 2.5/100,000 adults (5,139 hospi-
talizations) in 2000 to 4.1/100,000 (9,175 hospitalizations) in 2010, a 61.6% increase, 
and by over 200% for hospitalizations with any diagnosis of PTSD, from 28.6/100,000 
to 87.7/100,000. For hospitalizations with PTSD as the primary diagnosis, the mean 
(standard deviation [SD]) LOS increased slightly, from 5.7 (7.6) days in 2000 to 6.0 
(6.9) days in 2010, while mean (SD) costs increased by 23.2%, from $5,138 ($6,440) 
in 2000 to $6,330 ($7,281) in 2010. Finally, from 2000 to 2010, the estimated total 
(aggregate) cost of PTSD-related hospitalizations increased by 129% ($26.3 million 
to $60.3 million) for primary PTSD diagnosis hospitalizations and 471% ($435 million 
to $2.49 billion) for any PTSD diagnosis. cOnclusiOns: PTSD-related hospitaliza-
tion rates in the US have increased during the first decade of the 2000s, with the 
total inpatient cost burden increasing at an even greater rate. Further research to 
better understand factors which may be influencing the observed growth in rates of 
PTSD-related hospitalization in the US (e.g., changing diagnostic criteria; increasing 
numbers of servicemen and women returning from military combat settings, which 
is an established PTSD risk factor) is warranted.
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Objectives: Buprenorphine/naloxone (BUP/NAL) combination is a treatment for 
the opioid dependence. Earlier studies showed that some patients, here, alternated 
between periods on and off treatment. The aim of this study was to compare health 
care resource utilization and costs between these patients and patients treated 
continuously. MethOds: Statistical analyses were conducted on a Medicaid insur-
disorders (26.5% vs. 13.6%; p< 0.001). In the follow-up period, high-cost patients 
continued to have higher rates of non-opioid substance abuse diagnoses (53.0% 
vs. 47.2%; p< 0.001) and psychotic disorders (67.1% vs. 47.5%; p< 0.001). The mean 
follow-up period health care costs of high-cost patients was $89,177 (vs. $11,653 
for low-cost patients (p< 0.001)), of which 38.8% was attributed to inpatient, 21.9% 
to outpatient, 18.6% to emergency department , 4.9% to rehabilitation facility, and 
11.0% to prescription drugs costs. cOnclusiOns: High-cost patients diagnosed 
with opioid abuse are complicated patients with high rates of pre-existing and 
concurrent chronic comorbidities and mental health conditions.
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enrollees
Juarez D.1, Davis J.2
1University of Hawaii at Hilo, Honolulu, HI, USA, 2John A. Burns School of Medicine, Honolulu, 
HI, USA
Objectives: In the US, over 5 million people suffer from Alzheimer’s Disease (AD). 
The objective of this study is to estimate direct medical costs attributable to AD for 
Medicare enrollees in 2008 and 2010 according to cost category. MethOds: Data 
were from the Centers for Medicare & Medicaid Services (CMS) chronic conditions 
public use files in which each record is a profile defined by all combinations of age 
category, gender, chronic conditions, and dual-eligibility status. For each profile, cost 
measures generated from claims data are provided in the form of averages by cost 
category. Our study population (n= 23.7m) included Medicare enrollees in years 2008 
and 2010 who: 1) had 12 months enrollment; 2) did not have dual eligibility; 3) were 
age 65 and over. We examined costs of hospital admissions, skilled nursing facility, 
physician and other provider visits, outpatient visits, and prescriptions medica-
tions. To determine the cost associated with AD, we estimated multivariable OLS 
linear regression models with cost as the dependent variable and a dichotomous 
AD indicator as the primary independent variable, adjusted for age, gender and 
other chronic conditions and weighted using frequency counts. Results: Adjusted 
costs associated with AD were highest for skilled nursing facility use, medications, 
and inpatient services, at $1680, $1280 and $1114, respectively, in 2010. Of the 11 
chronic conditions examined, AD was the most costly in terms of added medication 
expenditures, with added annual costs $300 more than the next closest condition, 
chronic obstructive pulmonary disorder (COPD, Table). It was also the second most 
costly condition in terms of skilled nursing facility costs, surpassed only by stroke in 
adjusted analyses. cOnclusiOns: Interventions, including treatment for reversible 
causes, lifestyle modification, and use of cost-effective treatments, may be needed 
to stem cost increases attributable to AD, particularly as the population ages.
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Objectives: Schizophrenia is a mental disease of chronic nature that may often 
require long time hospitalizations to be controlled. One of the major issues in con-
trolling Sc is adherence to treatment. Long-term release paliperidone palmitate 
administered intramuscularly once a month improved treatment compliance and 
diminished hospitalization rates. Our goal was to estimate the costs of hospitaliza-
tion for schizophrenic patients in Brazil (private setting) and to calculate the mon-
etary impact of adopting LRPP in an outpatient scenario. MethOds: We searched a 
database of claims of five health plans in order to identify patients with schizophre-
nia. Then, we retrieved all hospitals bills for each patient and determined the final 
cost of admissions. Only direct costs were considered: medication, medical visits, 
ancillary fees, etc. To project the impact of the adoption of LRPP, we estimated that 
hospitalization rates would be reduced by 31.5% for patients admitted for less than 
one year and 35.9% for those hospitalized for up to two years, according to data from 
randomized trials. Results: We identified 18 admissions due to schizophrenia. 
Patients had a mean age of 43.4 years. Mean length of hospitalization was 126.4 days, 
corresponding to a total of 2275 days for all patients. Total hospitalization cost was 
R$ 604 889 (US$ 252 037), mean of R$ 33 604 (US$ 14 000) per hospitalization. If LRPP 
was adopted, the cost to treat these patients would be cut down to R$ 130 974 (US$ 
54 572), a reduction of 21,65%. cOnclusiOns: Based on real world data, Sc hospi-
talization costs may be reduced by 21% if outpatient treatment with LRPP is adopted.
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Objectives: To examine the economic burden and health care utilizations of bipo-
lar disorder patients in the U.S. veteran population. MethOds: A retrospective data-
base analysis was performed using the Veterans Health Administration Medical SAS 
datasets from October 1, 2007 through September 30, 2012. Adult patients diagnosed 
with bipolar disorder were identified using International Classification of Disease, 
9th Revision, Clinical Modification (ICD-9-CM) diagnosis codes 296.0x, 296.1x, 296.4x, 
296.5x, 296.6x, 296.7x and 296.8x. The first diagnosis date was defined as the index 
date for the bipolar disorder cohort. A comparator cohort of patients without a 
bipolar disorder diagnosis was created using 1:1 propensity score matching to adjust 
for demographic characteristics and baseline Charlson Comorbidity Index scores. 
The index date for the comparator cohort was randomly chosen to reduce selec-
tion bias. One-year continuous enrollment was required before and after the index 
date for both cohorts. Study outcomes, including health care costs and utilizations, 
were compared between the disease and comparator cohorts. Results: After 1:1 
matching, a total of 187,530 patients with proportionate baseline characteristics 
